Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.Jacob Schachter, Caroline Robert, Bart Neyns et al.|Journal of Clinical Oncology|2016Cited by 68
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).Georgina V. Long, Antoni Ribas, Omid Hamid et al.|Journal of Clinical Oncology|2016Cited by 12
Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma PatientsSarah Zhou, Ivan V. Litvinov, Daniel Sikorski et al.|Cancers|2021Cited by 12
Restructuring Skin Cancer Care in Ontario: A Provincial PlanJohn Milkovich, Frances C. Wright, Timothy P. Hanna et al.|Current Oncology|2021Cited by 4
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative IntentSudha Rajagopal, Teresa M. Petrella, Xiaomei Yao et al.|Clinical Oncology|2024Cited by 4